BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Ren Z, Zhu K, Kang H, Lu M, Qu Z, Lu L, Song T, Zhou W, Wang H, Yang W, Wang X, Yang Y, Shi L, Bai Y, Guo X, Ye S. Randomized Controlled Trial of the Prophylactic Effect of Urea-Based Cream on Sorafenib-Associated Hand-Foot Skin Reactions in Patients With Advanced Hepatocellular Carcinoma. JCO 2015;33:894-900. [DOI: 10.1200/jco.2013.52.9651] [Cited by in Crossref: 71] [Cited by in F6Publishing: 30] [Article Influence: 10.1] [Reference Citation Analysis]
Number Citing Articles
1 Luo XY, Wu KM, He XX. Advances in drug development for hepatocellular carcinoma: clinical trials and potential therapeutic targets. J Exp Clin Cancer Res 2021;40:172. [PMID: 34006331 DOI: 10.1186/s13046-021-01968-w] [Cited by in Crossref: 3] [Cited by in F6Publishing: 5] [Article Influence: 3.0] [Reference Citation Analysis]
2 Chanprapaph K, Rutnin S, Vachiramon V. Multikinase Inhibitor-Induced Hand-Foot Skin Reaction: A Review of Clinical Presentation, Pathogenesis, and Management. Am J Clin Dermatol 2016;17:387-402. [PMID: 27221667 DOI: 10.1007/s40257-016-0197-1] [Cited by in Crossref: 27] [Cited by in F6Publishing: 25] [Article Influence: 4.5] [Reference Citation Analysis]
3 Zhu XD, Sun HC. Emerging agents and regimens for hepatocellular carcinoma. J Hematol Oncol. 2019;12:110. [PMID: 31655607 DOI: 10.1186/s13045-019-0794-6] [Cited by in Crossref: 35] [Cited by in F6Publishing: 38] [Article Influence: 11.7] [Reference Citation Analysis]
4 Kume T, Shimizu R, Akiyama K, Tsuchiya T, Shino M, Ikeda T, Iwai S. Hand-foot syndrome and risk factors for occurrence in hematopoietic stem cell transplantation recipients. Support Care Cancer 2021. [PMID: 34536133 DOI: 10.1007/s00520-021-06573-3] [Reference Citation Analysis]
5 Kao S, Friedman A. Supportive Oncodermatology: Addressing dermatologic adverse events associated with oncologic therapies. Oncology Issues 2018;33:64-75. [DOI: 10.1080/10463356.2018.1525994] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
6 Naganuma A, Hoshino T, Ohno N, Ogawa Y, Murakami T, Horiguchi S, Uehara D, Suzuki Y, Hatanaka T, Kudo T, Ishihara H, Sato K, Kakizaki S, Takagi H. β-Hydroxy-β-methyl Butyrate/L-Arginine/L-Glutamine Supplementation for Preventing Hand-Foot Skin Reaction in Sorafenib for Advanced Hepatocellular Carcinoma. In Vivo 2019;33:155-61. [PMID: 30587616 DOI: 10.21873/invivo.11452] [Cited by in Crossref: 3] [Cited by in F6Publishing: 3] [Article Influence: 1.0] [Reference Citation Analysis]
7 Ferreira MN, Ramseier JY, Leventhal JS. Dermatologic conditions in women receiving systemic cancer therapy. Int J Womens Dermatol 2019;5:285-307. [PMID: 31909148 DOI: 10.1016/j.ijwd.2019.10.003] [Cited by in Crossref: 5] [Cited by in F6Publishing: 1] [Article Influence: 1.7] [Reference Citation Analysis]
8 Katayama K, Kiyota R, Imai T, Abe Y, Nawa T, Wada H, Ohkawa K. Factors Affecting Therapeutic Effects in 17 Patients with Advanced Hepatocellular Carcinoma Who Were Treated with Sorafenib for More than 12 Months. Case Rep Oncol 2018;11:711-20. [PMID: 30483103 DOI: 10.1159/000493853] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.5] [Reference Citation Analysis]
9 Lin SM, Lu SN, Chen PT, Jeng LB, Chen SC, Hu CT, Yang SS, Le Berre MA, Liu X, Mitchell DY, Prins K, Grevel J, Peña CA, Meinhardt G. HATT: a phase IV, single-arm, open-label study of sorafenib in Taiwanese patients with advanced hepatocellular carcinoma. Hepatol Int 2017;11:199-208. [PMID: 27909950 DOI: 10.1007/s12072-016-9774-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
10 Pandy JGP, Franco PIG, Li RK. Prophylactic strategies for hand-foot syndrome/skin reaction associated with systemic cancer treatment: a meta-analysis of randomized controlled trials. Support Care Cancer 2022. [PMID: 35655045 DOI: 10.1007/s00520-022-07175-3] [Reference Citation Analysis]
11 Fan Y, Xue H, Zheng H. Systemic Therapy for Hepatocellular Carcinoma: Current Updates and Outlook. JHC 2022;Volume 9:233-63. [DOI: 10.2147/jhc.s358082] [Reference Citation Analysis]
12 Guo J, Ma J, Sun Y, Qin S, Ye D, Zhou F, He Z, Sheng X, Bi F, Cao D, Chen Y, Huang Y, Liang H, Liang J, Liu J, Liu W, Pan Y, Shu Y, Song X, Wang W, Wang X, Wu X, Xie X, Yao X, Yu S, Zhang Y, Zhou A; written; CSCO Renal Cell Carcinoma Committee. Chinese guidelines on the management of renal cell carcinoma (2015 edition). Ann Transl Med. 2015;3:279. [PMID: 26697439 DOI: 10.3978/j.issn.2305-5839.2015.11.21] [Cited by in F6Publishing: 8] [Reference Citation Analysis]
13 Jatoi A, Ou FS, Ahn DH, Zemla TJ, Le-Rademacher JG, Boland P, Ciombor KK, Jacobs NL, Pasche B, Cleary JM, McCune JS, Pedersen KS, Barzi A, Chiorean EG, Heying EN, Lenz HJ, Sloan JA, Grothey A, Lacouture ME, Bekaii-Saab T. Preemptive Versus Reactive Topical Clobetasol for Regorafenib-Induced Hand-Foot Reactions: A Preplanned Analysis of the ReDOS Trial. Oncologist 2021;26:610-8. [PMID: 33604969 DOI: 10.1002/onco.13730] [Reference Citation Analysis]
14 Cury-Martins J, Eris APM, Abdalla CMZ, Silva GB, Moura VPT, Sanches JA. Management of dermatologic adverse events from cancer therapies: recommendations of an expert panel. An Bras Dermatol 2020;95:221-37. [PMID: 32165025 DOI: 10.1016/j.abd.2020.01.001] [Cited by in Crossref: 7] [Cited by in F6Publishing: 4] [Article Influence: 3.5] [Reference Citation Analysis]
15 Nawa T, Katayama K, Kiyota R, Imai T, Abe Y, Hasegawa N, Takada R, Fukutake N, Ikezawa K, Sakakibara M, Fujita M, Ohkawa K. Development of a thrombus in the superior mesenteric artery associated with sequential therapy with tyrosine kinase inhibitors for hepatocellular carcinoma. Clin J Gastroenterol 2020;13:247-51. [PMID: 31317371 DOI: 10.1007/s12328-019-01021-6] [Cited by in Crossref: 1] [Article Influence: 0.3] [Reference Citation Analysis]
16 Batson S, Burton H. A Systematic Review of Methods for Handling Missing Variance Data in Meta-Analyses of Interventions in Type 2 Diabetes Mellitus. PLoS One 2016;11:e0164827. [PMID: 27749930 DOI: 10.1371/journal.pone.0164827] [Cited by in Crossref: 12] [Cited by in F6Publishing: 6] [Article Influence: 2.0] [Reference Citation Analysis]
17 Piquero-Casals J, Morgado-Carrasco D, Granger C, Trullàs C, Jesús-Silva A, Krutmann J. Urea in Dermatology: A Review of its Emollient, Moisturizing, Keratolytic, Skin Barrier Enhancing and Antimicrobial Properties. Dermatol Ther (Heidelb) 2021;11:1905-15. [PMID: 34596890 DOI: 10.1007/s13555-021-00611-y] [Reference Citation Analysis]
18 Kaneko S, Ikeda K, Matsuzaki Y, Furuse J, Minami H, Okayama Y, Sunaya T, Ito Y, Inuyama L, Okita K. Safety and effectiveness of sorafenib in Japanese patients with hepatocellular carcinoma in daily medical practice: interim analysis of a prospective postmarketing all-patient surveillance study. J Gastroenterol 2016;51:1011-21. [PMID: 26931117 DOI: 10.1007/s00535-016-1173-5] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 3.5] [Reference Citation Analysis]
19 Schwartz G, Darling JO, Mindo M, Damicis L. Management of Adverse Events Associated with Cabozantinib Treatment in Patients with Advanced Hepatocellular Carcinoma. Target Oncol 2020;15:549-65. [PMID: 32770441 DOI: 10.1007/s11523-020-00736-8] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 1.5] [Reference Citation Analysis]
20 Cheng L, Fu H, Jin Y, Sa R, Chen L. Clinicopathological Features Predict Outcomes in Patients with Radioiodine-Refractory Differentiated Thyroid Cancer Treated with Sorafenib: A Real-World Study. Oncologist 2020;25:e668-78. [PMID: 31957916 DOI: 10.1634/theoncologist.2019-0633] [Cited by in Crossref: 5] [Cited by in F6Publishing: 2] [Article Influence: 2.5] [Reference Citation Analysis]
21 Gockel I, Hoffmeister A, Lordick F. [Neoadjuvant therapy for tumors of the upper gastrointestinal tract : Complication management]. Chirurg 2015;86:1014-22. [PMID: 26374651 DOI: 10.1007/s00104-015-0077-x] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
22 Xie Y, Wang Q, Hu T, Chen R, Wang J, Chang H, Peng X, Cheng J. Effect of a novel soaking solution used in patients with hand-foot syndrome as a result of capecitabine treatment: A randomized and self-controlled trial. Clinical Breast Cancer 2022. [DOI: 10.1016/j.clbc.2022.01.009] [Reference Citation Analysis]
23 Costa R, Carneiro BA, Chandra S, Pai SG, Chae YK, Kaplan JB, Garrett HB, Agulnik M, Kopp PA, Giles FJ. Spotlight on lenvatinib in the treatment of thyroid cancer: patient selection and perspectives. Drug Des Devel Ther 2016;10:873-84. [PMID: 27013865 DOI: 10.2147/DDDT.S93459] [Cited by in Crossref: 21] [Cited by in F6Publishing: 14] [Article Influence: 3.5] [Reference Citation Analysis]
24 Qin F, Yu H, Xu CR, Chen HH, Bai JL. Safety of axitinib and sorafenib monotherapy for patients with renal cell carcinoma: a meta-analysis. J Biomed Res 2018;32:30-8. [PMID: 29353818 DOI: 10.7555/JBR.32.20170080] [Reference Citation Analysis]
25 Yu R, Wu X, Jia L, Lou Y. Effect of Chinese Herbal Compound LC09 on Patients With Capecitabine-Associated Hand-Foot Syndrome: A Randomized, Double-Blind, and Parallel-Controlled Trial. Integr Cancer Ther 2020;19:1534735420928466. [PMID: 32597691 DOI: 10.1177/1534735420928466] [Reference Citation Analysis]
26 Raoul JL, Adhoute X, Penaranda G, Perrier H, Castellani P, Oules V, Bourlière M. Sorafenib: Experience and Better Manage-ment of Side Effects Improve Overall Survival in Hepatocellular Carcinoma Patients: A Real-Life Retrospective Analysis. Liver Cancer 2019;8:457-67. [PMID: 31799203 DOI: 10.1159/000497161] [Cited by in Crossref: 12] [Cited by in F6Publishing: 11] [Article Influence: 4.0] [Reference Citation Analysis]
27 Winters AC, Bedier F, Saab S. Management of Side Effects of Systemic Therapies for Hepatocellular Carcinoma: Guide for the Hepatologist. Clin Liver Dis 2020;24:755-69. [PMID: 33012457 DOI: 10.1016/j.cld.2020.07.008] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
28 Lacouture ME, Kopsky DJ, Lilker R, Damstra F, van der Linden MHM, Freites-Martinez A, Nagel MPM. Podiatric Adverse Events and Foot Care in Cancer Patients and Survivors Awareness, Education, and Literature Review. J Am Podiatr Med Assoc 2018;108:508-16. [PMID: 30742505 DOI: 10.7547/17-010] [Reference Citation Analysis]
29 Gill J, Dominguez AR. Cutaneous Manifestations of Chemotherapeutic Drugs. Curr Derm Rep 2016;5:58-69. [DOI: 10.1007/s13671-016-0130-0] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
30 Ostwal V, Gupta T, Chopra S, Lewis S, Goel M, Patkar S, Shetty N, Ramaswamy A. Tolerance and adverse event profile with sorafenib in Indian patients with advanced hepatocellular carcinoma. South Asian J Cancer 2017;6:144-6. [PMID: 29404288 DOI: 10.4103/sajc.sajc_44_17] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
31 Cabanillas ME, Ryder M, Jimenez C. Targeted Therapy for Advanced Thyroid Cancer: Kinase Inhibitors and Beyond. Endocr Rev 2019;40:1573-604. [PMID: 31322645 DOI: 10.1210/er.2019-00007] [Cited by in Crossref: 49] [Cited by in F6Publishing: 54] [Article Influence: 24.5] [Reference Citation Analysis]
32 McLellan B, Ciardiello F, Lacouture ME, Segaert S, Van Cutsem E. Regorafenib-associated hand-foot skin reaction: practical advice on diagnosis, prevention, and management. Ann Oncol. 2015;26:2017-2026. [PMID: 26034039 DOI: 10.1093/annonc/mdv244] [Cited by in Crossref: 61] [Cited by in F6Publishing: 46] [Article Influence: 8.7] [Reference Citation Analysis]
33 Muzellec L, Bourien H, Edeline J. Patients' Experience of Systemic Treatment of Hepatocellular Carcinoma: A Review of the Impact on Quality of Life. Cancers (Basel) 2021;14:179. [PMID: 35008343 DOI: 10.3390/cancers14010179] [Reference Citation Analysis]
34 Terashima T, Yamashita T, Takata N, Takeda Y, Kido H, Iida N, Kitahara M, Shimakami T, Takatori H, Arai K, Kawaguchi K, Kitamura K, Yamashita T, Sakai Y, Mizukoshi E, Honda M, Kaneko S. Safety and efficacy of sorafenib followed by regorafenib or lenvatinib in patients with hepatocellular carcinoma. Hepatol Res 2021;51:190-200. [PMID: 33197087 DOI: 10.1111/hepr.13588] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.5] [Reference Citation Analysis]
35 Zenda S, Ryu A, Takashima A, Arai M, Takagi Y, Miyaji T, Mashiko T, Shimizu Y, Yamazaki N, Morizane C, Yamaguchi T, Kawaguchi T, Hanai A, Uchitomi Y, Oshiba F. Hydrocolloid dressing as a prophylactic use for hand-foot skin reaction induced by multitargeted kinase inhibitors: protocol of a phase 3 randomised self-controlled study. BMJ Open 2020;10:e038276. [PMID: 33028559 DOI: 10.1136/bmjopen-2020-038276] [Reference Citation Analysis]
36 Kwakman JJM, Elshot YS, Punt CJA, Koopman M. Management of cytotoxic chemotherapy-induced hand-foot syndrome. Oncol Rev 2020;14:442. [PMID: 32431787 DOI: 10.4081/oncol.2020.442] [Cited by in Crossref: 6] [Cited by in F6Publishing: 2] [Article Influence: 3.0] [Reference Citation Analysis]
37 Lien RY, Tung HH, Wu SL, Hu SH, Lu LC, Lu SF. Validation of the prophylactic efficacy of urea-based creams on sorafenib-induced hand-foot skin reaction in patients with advanced hepatocellular carcinoma: A randomised experiment study. Cancer Rep (Hoboken) 2021;:e1532. [PMID: 34910380 DOI: 10.1002/cnr2.1532] [Reference Citation Analysis]
38 Shou L, Shao T, Zhao F, Chen S, Chen Q, Shu Q. The Efficacy and Safety of the Shouzu Ning Decoction Treatment for Multi-Kinase Inhibitors-Associated Severe Hand-Foot Skin Reaction. Cancer Manag Res 2021;13:45-53. [PMID: 33442293 DOI: 10.2147/CMAR.S285002] [Reference Citation Analysis]
39 Iwase S, Ishiki H, Watanabe A, Shimada N, Chiba T, Kinkawa J, Tojo A. Mapisal Versus Urea Cream as Prophylaxis for Capecitabine-Associated Hand-Foot Syndrome. JCO 2016;34:391-391. [DOI: 10.1200/jco.2015.64.3932] [Cited by in Crossref: 2] [Article Influence: 0.3] [Reference Citation Analysis]
40 Worden F, Fassnacht M, Shi Y, Hadjieva T, Bonichon F, Gao M, Fugazzola L, Ando Y, Hasegawa Y, Park DJ, Shong YK, Smit JW, Chung J, Kappeler C, Meinhardt G, Schlumberger M, Brose MS. Safety and tolerability of sorafenib in patients with radioiodine-refractory thyroid cancer. Endocr Relat Cancer 2015;22:877-87. [PMID: 26370187 DOI: 10.1530/ERC-15-0252] [Cited by in Crossref: 31] [Cited by in F6Publishing: 11] [Article Influence: 5.2] [Reference Citation Analysis]
41 Keating GM. Sorafenib: A Review in Hepatocellular Carcinoma. Target Oncol. 2017;12:243-253. [PMID: 28299600 DOI: 10.1007/s11523-017-0484-7] [Cited by in Crossref: 95] [Cited by in F6Publishing: 107] [Article Influence: 19.0] [Reference Citation Analysis]
42 Lin Y, Wang C, Gao W, Cui R, Liang J. Overwhelming rapid metabolic and structural response to apatinib in radioiodine refractory differentiated thyroid cancer. Oncotarget 2017;8:42252-61. [PMID: 28178685 DOI: 10.18632/oncotarget.15036] [Cited by in Crossref: 30] [Cited by in F6Publishing: 31] [Article Influence: 7.5] [Reference Citation Analysis]
43 Zhu XD, Tang ZY, Sun HC. Targeting angiogenesis for liver cancer: Past, present, and future. Genes Dis 2020;7:328-35. [PMID: 32884987 DOI: 10.1016/j.gendis.2020.03.010] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 5.5] [Reference Citation Analysis]
44 Granito A, Marinelli S, Negrini G, Menetti S, Benevento F, Bolondi L. Prognostic significance of adverse events in patients with hepatocellular carcinoma treated with sorafenib. Therap Adv Gastroenterol 2016;9:240-9. [PMID: 26929785 DOI: 10.1177/1756283X15618129] [Cited by in Crossref: 43] [Cited by in F6Publishing: 23] [Article Influence: 7.2] [Reference Citation Analysis]